Table 1 The clinical and laboratory characteristics of all patients and subgroups stratified by the severity of EPVS.

From: Serum Uric Acid is Independently Associated with Enlarged Perivascular Spaces

Characteristics

Total sample

BG-EPVS

F or chi-square values

P value

WM-EPVS

F or chi-square values

P value

mild

moderate

severe

mild

moderate

severe

n

665

225

248

192

—

—

138

367

160

—

—

Age, years

63 ± 11

58 ± 10

62 ± 10

70 ± 10

74.75

<0.001

62 ± 11

63 ± 11

62 ± 11

1.67

0.189

Sex, male (%)

445(70%)

154(68.4%)

176(71.0%)

115(60.0%)

6.35

0.042

91(65.9%)

234(63.8%)

120(75%)

6.43

0.040

Smoking (%)

335(50%)

127(56.4%)

132(53.2%)

76(39.6%)

13.07

0.001

72(52.2%)

176(48.0%)

87(54.4%)

2.06

0.357

Alcohol (%)

227(34%)

86(38.2%)

96(38.7%)

45(23.4%)

13.75

0.001

44(31.9%)

113(30.8%)

70(43.8%)

8.72

0.013

Hypertension (%)

426(64%)

132(58.7%)

153(61.7%)

141(73.4%)

10.78

0.005

82(59.4%)

235(64.0%)

109(68.1%)

2.44

0.296

Diabetes (%)

209(31%)

72(32.0%)

79(31.9%)

58(30.2%)

0.19

0.910

42(30.4%)

124(33.8%)

43(26.9%)

2.55

0.280

CAD (%)

77(11.6%)

20(8.9%)

27(10.9%)

30(15.6%)

4.78

0.092

15(10.9%)

41(11.1%)

21(13.1%)

1.23

0.541

BMI, kg/m2

25.26 ± 3.21

25.11 ± 2.85

25.33 ± 3.31

25.35 ± 3.49

0.36

0.699

24.88 ± 3.15

25.25 ± 3.24

25.60 ± 3.19

1.86

0.156

HDL, mmol/L

1.26 ± 0.36

1.34 ± 0.34

1.25 ± 0.35

1.19 ± 0.37

8.94

<0.001

1.32 ± 0.34

1.26 ± 0.37

1.23 ± 0.34

2.34

0.098

LDL, mmol/L

2.69 ± 0.77

2.71 ± 0.74

2.68 ± 0.76

2.66 ± 0.83

0.19

0.830

2.63 ± 0.84

2.69 ± 0.74

2.73 ± 0.79

0.70

0.497

TC, mmol/L

4.74 ± 1.09

4.79 ± 1.02

4.70 ± 1.15

4.72 ± 1.10

0.43

0.650

4.74 ± 1.06

4.75 ± 1.13

4.71 ± 1.02

0.06

0.945

TG, mmol/L

1.77 ± 1.28

1.85 ± 1.46

1.73 ± 1.31

1.72 ± 1.00

0.75

0.475

1.86 ± 1.35

1.77 ± 1.34

1.68 ± 1.06

0.80

0.450

HbA1c, %

6.80 ± 1.92

6.65 ± 2.22

6.79 ± 1.74

6.98 ± 1.70

1.64

0.195

6.60 ± 1.72

6.87 ± 1.82

6.80 ± 2.24

1.02

0.361

Glu, mmol/L

6.69 ± 2.93

6.68 ± 3.38

6.58 ± 2.53

6.85 ± 2.85

0.45

0.635

6.55 ± 2.94

6.77 ± 3.04

6.64 ± 2.66

0.30

0.738

BUN, mmol/L

4.99 ± 2.80

4.91 ± 3.95

5.10 ± 2.22

4.94 ± 1.56

0.31

0.733

4.98 ± 2.67

5.12 ± 3.24

4.71 ± 1.49

1.20

0.302

Creatinine, umol/L

83 ± 28

81 ± 29

85 ± 31

83 ± 21

1.31

0.271

86 ± 36

82 ± 27

84 ± 22

0.80

0.449

SUA, mg/dl

4.98 ± 1.40

4.75 ± 1.40

4.98 ± 1.38

5.25 ± 1.40

6.77

0.001

4.88 ± 1.37

4.87 ± 1.39

5.31 ± 1.41

5.86

0.003

hs-CRP, mmol/L

3.05 ± 3.65

2.59 ± 2.94

3.35 ± 4.19

3.17 ± 3.61

2.73

0.066

3.13 ± 3.73

2.93 ± 3.56

3.23 ± 3.77

0.42

0.655

Fazekas scale

2.92 ± 1.72

1.88 ± 1.27

2.92 ± 1.63

4.13 ± 1.49

119.85

<0.001

2.43 ± 1.67

3.18 ± 1.74

2.72 ± 1.56

11.47

<0.001

  1. BG, basal ganglia; WM, white matter; CAD, coronary artery atherosclerosis disease; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, total triglyceride; BUN, blood urea nitrogen; hs-CRP, hypersensitivity C response protein. Continuous variables are expressed as the mean values ± standard deviation and were compared with analysis of variance. Categorical variables were expressed as absolute numbers and percentages and were compared with chi-squared tests. Statistical significance was accepted at p < 0.05.
Back to article page